---
title: "Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288107555.md"
description: "Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News"
datetime: "2026-05-29T11:15:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288107555.md)
  - [en](https://longbridge.com/en/news/288107555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288107555.md)
---

# Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News

### Related Stocks

- [VCYT.US](https://longbridge.com/en/quote/VCYT.US.md)

## Related News & Research

- [Veracyte to present at Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294109706.md)
- [Veracyte Announces First Quarter 2026 Financial Results | VCYT Stock News](https://longbridge.com/en/news/285256826.md)
- [Eikon Therapeutics doses first patient in TeLuRide-008 Phase 2/3 NSCLC trial of EIK1001 combo](https://longbridge.com/en/news/293924702.md)
- [Imunon announces press release available](https://longbridge.com/en/news/293625903.md)
- [OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer | VCYT Stock News](https://longbridge.com/en/news/287277324.md)